ATE264313T1 - Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore - Google Patents

Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore

Info

Publication number
ATE264313T1
ATE264313T1 AT99944335T AT99944335T ATE264313T1 AT E264313 T1 ATE264313 T1 AT E264313T1 AT 99944335 T AT99944335 T AT 99944335T AT 99944335 T AT99944335 T AT 99944335T AT E264313 T1 ATE264313 T1 AT E264313T1
Authority
AT
Austria
Prior art keywords
hppar
gamma
thiazole derivatives
substituted oxazole
alpha activators
Prior art date
Application number
AT99944335T
Other languages
English (en)
Inventor
Jon Loren Collins
Milana Dezube
Jeffrey Alan Oplinger
Timothy Mark Willson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE264313T1 publication Critical patent/ATE264313T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99944335T 1998-08-07 1999-08-05 Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore ATE264313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817118.4A GB9817118D0 (en) 1998-08-07 1998-08-07 Pharmaceutical compounds
PCT/EP1999/005666 WO2000008002A1 (en) 1998-08-07 1999-08-05 SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS

Publications (1)

Publication Number Publication Date
ATE264313T1 true ATE264313T1 (de) 2004-04-15

Family

ID=10836805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99944335T ATE264313T1 (de) 1998-08-07 1999-08-05 Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore

Country Status (31)

Country Link
US (1) US6498174B1 (de)
EP (1) EP1102757B1 (de)
JP (1) JP2002522426A (de)
KR (1) KR20010085340A (de)
CN (1) CN1321152A (de)
AP (1) AP2001002066A0 (de)
AR (1) AR020001A1 (de)
AT (1) ATE264313T1 (de)
AU (1) AU5731099A (de)
BR (1) BR9912866A (de)
CA (1) CA2339773A1 (de)
CO (1) CO5070570A1 (de)
CZ (1) CZ2001490A3 (de)
DE (1) DE69916457T2 (de)
EA (1) EA200100105A1 (de)
EE (1) EE200100074A (de)
ES (1) ES2220110T3 (de)
GB (1) GB9817118D0 (de)
HR (1) HRP20010095A2 (de)
HU (1) HUP0103469A3 (de)
ID (1) ID29543A (de)
IL (1) IL141248A0 (de)
IS (1) IS5840A (de)
MA (1) MA26668A1 (de)
NO (1) NO20010628L (de)
PE (1) PE20000947A1 (de)
PL (1) PL345882A1 (de)
SK (1) SK1962001A3 (de)
TR (1) TR200100372T2 (de)
WO (1) WO2000008002A1 (de)
ZA (1) ZA200100983B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
EP1589006A1 (de) * 1999-09-22 2005-10-26 Bristol-Myers Squibb Company Oxa- und Thiazolderivate sowie ihre Verwendung gegen Diabetes und Fettsucht
TW200514783A (en) * 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
US7241785B2 (en) 2001-03-23 2007-07-10 Takeda Pharmaceutical Company Limited Five-membered heterocyclic alkanoic acid derivative
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
IL158589A0 (en) * 2001-05-15 2004-05-12 Hoffmann La Roche Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
AU2002308891B2 (en) * 2001-05-29 2007-09-06 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
MXPA03010811A (es) * 2001-05-29 2004-02-27 Kyoto Pharma Ind Compuestos heterociclico y uso farmaceutico.
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200300681A (en) 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
JP3884736B2 (ja) * 2002-01-17 2007-02-21 トーアエイヨー株式会社 ハロゲノベンジルアミノプロピオン酸誘導体
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
KR100621294B1 (ko) 2002-07-03 2006-09-06 에프. 호프만-라 로슈 아게 옥사졸 유도체 및 이의 인슐린 증감제로서의 용도
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP1537091B1 (de) * 2002-08-30 2010-10-06 F. Hoffmann-La Roche AG Neue 2-arylthiazolverbindungen als ppar-alpha und -gamma agonisten
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
RS52397B (en) 2003-06-20 2013-02-28 F.Hoffmann-La Roche Ag PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
KR100744893B1 (ko) 2003-06-20 2007-08-01 에프. 호프만-라 로슈 아게 Ｄｐｐ-ｉｖ 저해제로서 헥사하이드로피리도아이소퀴놀린
EP1742904B1 (de) 2004-05-06 2012-10-31 The Regents of The University of California Substituierte enaminone, ihre derivate und verwendung
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100467456C (zh) * 2004-05-24 2009-03-11 北京摩力克科技有限公司 作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物
CN100344618C (zh) 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
EP2030974B1 (de) * 2006-06-13 2016-02-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Thiazol- nichtnukleosid-verbindungen, ihre herstellung, pharmazeutische zusammensetzung und ihre verwendung als antivirale mittel
GB0719180D0 (en) * 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2022052982A1 (zh) * 2020-09-14 2022-03-17 昭明泽康（北京）生物医药科技有限公司 PPARα（过氧化物酶体增殖物激活受体α）配体在制备药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JPH08325263A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CZ53699A3 (cs) * 1996-08-19 1999-07-14 Japan Tobacco Inc. Deriváty propionové kyseliny a jejich použití

Also Published As

Publication number Publication date
ID29543A (id) 2001-09-06
DE69916457D1 (de) 2004-05-19
AR020001A1 (es) 2002-03-27
CZ2001490A3 (cs) 2001-08-15
NO20010628L (no) 2001-04-06
GB9817118D0 (en) 1998-10-07
CO5070570A1 (es) 2001-08-28
JP2002522426A (ja) 2002-07-23
PL345882A1 (en) 2002-01-14
EA200100105A1 (ru) 2001-08-27
PE20000947A1 (es) 2000-09-22
MA26668A1 (fr) 2004-12-20
ES2220110T3 (es) 2004-12-01
WO2000008002A1 (en) 2000-02-17
EE200100074A (et) 2002-06-17
EP1102757B1 (de) 2004-04-14
HUP0103469A3 (en) 2002-08-28
US6498174B1 (en) 2002-12-24
TR200100372T2 (tr) 2001-09-21
HUP0103469A2 (hu) 2002-01-28
DE69916457T2 (de) 2005-04-14
NO20010628D0 (no) 2001-02-06
KR20010085340A (ko) 2001-09-07
AU5731099A (en) 2000-02-28
BR9912866A (pt) 2001-10-30
AP2001002066A0 (en) 2001-03-31
CN1321152A (zh) 2001-11-07
IL141248A0 (en) 2002-03-10
EP1102757A1 (de) 2001-05-30
ZA200100983B (en) 2002-03-05
HRP20010095A2 (en) 2002-02-28
CA2339773A1 (en) 2000-02-17
SK1962001A3 (en) 2001-11-06
IS5840A (is) 2001-02-05

Similar Documents

Publication Publication Date Title
ATE264313T1 (de) Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore
ATE265442T1 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
MA26855A1 (fr) Activateurs de glucokinases transolefiniques
ATE309236T1 (de) Epothilonderivate
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
EE200200341A (et) Asendatud oksasolidinoonid ja nende kasutamine
DE69711020D1 (de) Thiazole derivate als protein kinase c inhibitoren
DE69903143D1 (de) Chromanon und thiochromanon derivate
ATE233746T1 (de) Thiazole derivate
NO985227D0 (no) Alkylaminobenzothiazol og -benzoksazol - derivater
MA24632A1 (fr) Derives de 2-(4-aryl-ou heteroaryl-piperazine-1-ylmethyle)-1h- indole
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
NO20010654L (no) Ny anvendelse av taxoidderivater
DE69917777D1 (de) Benzazol-verbindungen und ihre verwendung
DE60223805D1 (de) Oxazol/thiazol-derivate als aktivatoren des hppar-alpha-rezeptors
ATE266012T1 (de) Thiazole derivate
ATE372989T1 (de) Azolinderivate
DE50001813D1 (de) Substituierte benzoxazole
ATE217621T1 (de) Thiazol-derivate
BR9800601A (pt) Produção de derivados de oxazol
NO20010655D0 (no) Ny anvendelse av taxoidderivater
ATE288902T1 (de) Oxazolidinon-derivate
SI1244642T1 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties